High-risk benign breast lesions: Current strategies in management

Cancer Control

Volumn 14, Issue 4, 2007, Pages 321-329

  Kiluk, John V ^a   Acs, Geza ^a   Hoover, Susan J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; ORNITHINE DECARBOXYLASE INHIBITOR; PLACEBO; RALOXIFENE; RETINOID; TAMOXIFEN;

BREAST APLASIA; BREAST BIOPSY; BREAST CANCER; BREAST FIBROADENOMA; BREAST HYPERPLASIA; BREAST LESION; BREAST PAPILLOMA; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; DRUG MECHANISM; ENDOMETRIUM CANCER; HIGH RISK PATIENT; HUMAN; LUNG CARCINOMA; MAMMOGRAPHY; MEDICAL LITERATURE; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; SCAR FORMATION; SCLEROSIS; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT PLANNING; UTERUS CANCER;

EID: 37249031385     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480701400402     Document Type: Review

References (87)

1. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-151.
2. Schnitt S, Connolly J. Pathology of benign breast disorders. In: Harris JR, Lippman ME, Morrow M, et al, eds. Diseases of the Breast. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2004.
3. Palli D, Rosselli Del Turco M, et al. Benign breast disease and breast cancer: a case-control study in a cohort in Italy. Int J Cancer. 1991;47:703-706.
4. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993;71:1258-1265.
5. Marshall LM, Hunter DJ, Connelly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997;6:297-301.
6. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med. 2005;143:446-457.
7. Wang J, Costantino JP, Tan-Chiu E, et al. Lower-category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst. 2004;96:616-620.
8. London SJ, Connolly JL, Schnitt SJ, et al. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992;267:941-944.
9. Page DL, Salhany KE, Jensen RA, et al. Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. Cancer. 1996;78:258-266.
10. Lewis JT, Hartmann LC, Vierkant RA, et al. An analysis of breast cancer risk in women with single, multiple, and atypical papilloma. Am J Surg Pathol. 2006;30:665-672.
11. Gendler LS, Feldman SM, Balassanian R, et al. Association of breast cancer with papillary lesions identified at percutaneous image-guided breast biopsy. Am J Surg. 2004;188:365-370.
12. Liberman L, Tornos C, Huzjan R, et al. Is surgical excision warranted after benign, concordant diagnosis of papilloma at percutaneous breast biopsy? AJR Am J Roentgenol. 2006;186:1328-1334.
13. Sydnor MK, Wilson JD, Hijaz TA, et al. Underestimation of the presence of breast carcinoma in papillary lesions initially diagnosed at core-needle biopsy. Radiology. 2007;242:58-62. Epub 2006 Nov 7.
14. Renshaw AA, Derhagopian RP, Tizol-Blanco DM, et al. Papillomas and atypical papillomas in breast core needle biopsy specimens: risk of carcinoma in subsequent excision. Am J Clin Pathol. 2004;122:217-221.
15. Ali-Fehmi R, Carolin K, Wallis T, et al. Clinicopathologic analysis of breast lesions associated with multiple papillomas. Hum Pathol. 2003;34:234-239.
16. King TA, Scharfenberg JC, Smetherman DH, et al. A better understanding of the term radial scar. Am J Surg. 2000;180:428-432; discussion 432-433.
17. Alleva DQ, Smetherman DH, Farr GH, et al. Radial scar of the breast: radiologic-pathologic correlation in 22 cases. Radiographics. 1999;19 Spec No:S27-S35; discussion S36-S37.
18. Frouge C, Tristant H, Guinebretière JM, et al. Mammographic lesions suggestive of radial scars: microscopic findings in 40 cases. Radiology. 1995;195:623-625.
19. Sewell CW. Pathology of benign and malignant breast disorders. Radiol Clin North Am. 1995;33:1067-1080.
20. Wellings SR, Alpers CE. Subgross pathologic features and incidence of radial scars in the breast. Hum Pathol. 1984;15:475-479.
21. Becker L, Trop I. David J, et al. Management of radial scars found at percutaneous breast biopsy. Can Assoc Radiol J. 2006;57:72-78.
22. Sanders ME, Page DL, Simpson JF, et al. Interdependence of radial scar and proliferative disease with respect to invasive breast cancinoma risk in patients with benign breast biopsies. Cancer. 2006;106:1453-1461.
23. Mokbel K, Price RK, Mostafa A, et al. Radial scar and carcinoma of the breast: microscopic findings in 32 cases. Breast. 1999;8:339-342.
24. Vega A, Garijo F. Radial scar and tubular carcinoma. Mammographic and sonographic findings. Acta Radiol. 1993;34:43-47.
25. Seidman JD, Ashton M, Lefkowitz M. Atypical apocrine adenosis of the breast: a clinicopathologic study of 37 patients with 8.7-year follow-up. Cancer. 1996;77:2529-2537.
26. Bianchi S, Palli D, Galli M, et al. Reproducibility of histological diagnoses and diagnostic accuracy of non palpable breast lesions. Pathol Res Pract. 1994;190:69-76.
27. Günhan-Bilgen I, Memifl A, Ustün EE, et al. Sclerosing adenosis: mammographic and ultrasonographic findings with clinical and histopathological correlation. Eur J Radiol. 2002;44:232-238.
28. Gill HK, Ioffe OB, Berg WA. When is a diagnosis of sclerosing adenosis acceptable at core biopsy? Radiology. 2003;228:50-57. Epub 2003 May 8.
29. Jensen RA, Page DL, Dupont WD, et al. Invasive breast cancer risk in women with sclerosing adenosis. Cancer. 1989;64:1977-1983.
30. Bodian CA, Perzin KH, Lattes R, et al. Prognostic significance of benign proliferative breast disease. Cancer. 1993;71:3896-3907.
31. Dupont WD, Page DL, Parl FF, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 1994;331:10-15.
32. Carter BA, Page DL, Schuyler P, et al. No elevation in long-term breast carcinoma risk for women with fibroadenomas that contain atypical hyperplasia. Cancer. 2001;92:30-36.
33. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
34. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727-2741. Epub 2006 Jun 5. Erratum in: JAMA. 2006;296:2926.
35. Collins LC, Baer HJ, Tamimi RM, et al. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer. 2007;109:180-187.
36. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997;6:297-301.
37. Page DL, Dupont WD, Rogers LW, et al. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55:2698-2708.
38. Page DL, Schuyler PA, Dupont WD, et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361:125-129. Erratum in: Lancet. 2003;361:1994.
39. Connolly J, Schnitt S, London S, et al. Both atypical lobular hyperplasia (ALH) and atypical ductal hyperplasia (ADH) predict for bilateral breast cancer risk. Lab Invest. 1992;66:13A.
40. Dmytrasz K, Tartter PI, Mizrachy H, et al. The significance of atypical lobular hyperplasia at percutaneous breast biopsy. Breast J. 2003;9:10-12.
41. Margenthaler JA, Duke D, Monsees BS, et al. Correlation between core biopsy and excisional biopsy in breast high-risk lesions. Am J Surg. 2006;192:534-537.
42. Bedei L, Falcini F, Sanna PA, et al. Atypical ductal hyperplasia of the breast: the controversial management of a borderline lesion: experience of 47 cases diagnosed at vacuum-assisted biopsy. Breast. 2006;15:196-202. Epub 2005 Aug 1.
43. Irfan K, Brem RF. Surgical and mammographic follow-up of papillary lesions and atypical lobular hyperplasia diagnosed with stereotactic vacuum-assisted biopsy. Breast J. 2002;8:230-233.
44. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol. 1991;15:209-221.
45. Greene T, Tartter PI, Smith SR, et al. The significance of surgical margins for patients with atypical ductal hyperplasia. Am J Surg. 2006;192:499-501.
46. Simpson PT, Gale T, Fulford LG, et al. The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res. 2003;5:258-262. Epub 2003 Jul 29.
47. Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005;23:5534-5541.
48. Page DL, Kidd TE, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22:1232-1239.
49. Franceschi S, Levi F, La Vecchia C, et al. Second cancers following in situ carcinoma of the breast. Int J Cancer. 1998;77:392-395.
50. Frykberg ER, Santiago F, Betsill WL, et al. Lobular carcinoma in situ of the breast. Surg Gynecol Obstet. 1987;164:285-301.
51. Shin SJ, Rosen PP. Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy. Arch Pathol Lab Med. 2002;126:697-701.
52. Lechner MC, Jackman RJ, Brem RF, et al. Lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous biopsy with surgical correlation: a multi-institutional study. Radiology. 1999;213:106.
53. Arpino G, Allred DC, Mohsin SK, et al. Lobular neoplasia on core-needle biopsy: clinical significance. Cancer. 2004;101:242-250.
54. Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42:737-769.
55. Newman L. Lobular carcinoma in situ: clinical management. In: Harris JR, Lippman ME, Morrow M, et al, eds. Diseases of the Breast. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2004.
56. Bradley SJ, Weaver DW, Bouwman DL. Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome. Am Surg. 1990;56:428-432.
57. Li CI, Malone KE, Saltzman BS, et al. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer. 2006;106:2104-2112.
58. Fisher ER, Land SR, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer. 2004;100:238-244.
59. Reis-Filho JS, Simpson PT, Jones C, et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol. 2005;207:1-13.
60. Sneige N, Wang J, Baker BA, et al. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol. 2002;15:1044-1050.
61. Giri DD, Dundas SA, Nottingham JF, et al. Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology. 1989;15:575-584.
62. Barnes R, Masood S. Potential value of hormone receptor assay in carcinoma in situ of breast. Am J Clin Pathol. 1990;94:533-537.
63. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817-824.
64. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98-101.
65. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998;352:93-97.
66. Bao T, Prowell T, Stearns V. Chemoprevention of Breast cancer: tamoxifen, raloxifene, and beyond. Am J Ther. 2006;13:337-348.
67. Cuzick, J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296-300.
68. Cummings SR, Eckert S, Krueger KA, et al. The effect on raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Mutiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189-2197. Erratum in: JAMA. 1999 Dec 8;282(22):2124.
69. Martino S, Cauley JA, Barrett-Conner E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751-1761.
70. Premkumar A, Venzon D, Avila N, et al. Gynocologic and hormonal effects of raloxifene in premenopausal subjects at high risk of developing breast cancer. AJR Am J Roentgenol. 2006;186(suppl 4):A121.
71. Geller BA, Vogel VG. Chemoprevention of breast cancer in postmenopausal women. Breast Dis. 2005-2006;24:79-92.
72. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802. Epub 2003 Oct 9.
73. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen verses tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98:1802-1810.
74. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092. Erratum in: N Engl J Med. 2004;351:2461.
75. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747-2757.
76. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst. 2005;97:1262-1271.
77. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
78. Kendall A, Dowsett M. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr Rel Cancer. 2006;13:827-837.
79. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004;291:2433-2440.
80. DuBois RN. Aspirin and breast cancer prevention: the estrogen connection. JAMA. 2004;291:2488-2489.
81. Thompson HJ, Herbst EJ, Meeker LD, et al. Effect of D, L-alpha-difluoromethylornithine on murine mammary carcinogenesis. Carcinogenesis. 1984;5:1649-1651.
82. Green JE, Shibata MA, Shibata E, et al. 2-Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res. 2001;61:7449-7455.
83. Fabian CJ, Kimler BF, Brady DA, et al. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res. 2002;8:3105-3117.
84. Moon RC, Pritchard JF, Mehta RG, et al. Suppression of rat mammary cancer development by N-(4-hydroxyphenyl) retinamide (4-HPR) following surgical removal of first palpable tumor. Carcinogenesis. 1989;10:1645-1649.
85. Mehta RG, Moon RC, Hawthorne M, et al. Distribution of fenretinide in the mammary gland of breast cancer patients. Eur J Cancer. 1991;27:138-141.
86. Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999;91:1847-1856.
87. Jeffrey SS, Pollack JR. The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. Breast Cancer Res. 2003;5:320-328. Epub 2003 Oct 9.